SCHEMBL3247591

SCHEMBL3247591

CCCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)N(C)C4CCOCC4)cc3c12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
HPGD P15428 6/20 0.41
MAPT P10636 5/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 4/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 5/20 0.38
POLB P06746 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.36
RORC P51449 1/20 0.36
USP2 O75604 2/20 0.36
CASP3 P42574 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250843 0.94 MAPT (0.44) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3241985 0.91 MAPT (0.42) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3254222 0.91 MAPT (0.41) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL13928160 0.90 MAPT (0.42) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3254901 0.88 KDM4E (0.38) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3248642 0.87 GAA (0.43) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3250616 0.85 HSD17B10 (0.39) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3251345 0.83 KDM4E (0.38) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL3252520 0.83 KDM4E (0.38) ALDH1A1HPGDMAPTLMNAKDM4E
SCHEMBL13950882 0.82 KDM4E (0.38) ALDH1A1HPGDMAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 ALDH1A1 3830/4885HPGD 882/4885MAPT 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.